Medical cannabis: “restrictive” guidance lets patients down, say campaigners
BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4654 (Published 01 November 2018) Cite this as: BMJ 2018;363:k4654- Richard Hurley
- BMJ
GPs have been advised not to prescribe unlicensed drugs containing naturally occurring cannabinoids but to refer patients at “the appropriate point in their treatment pathway” to specialists registered with the General Medical Council.
The guidance from NHS England advises that patients should not approach GPs to ask for these products.1
Very few patients are expected to benefit from the change in the law that comes into force on 1 November,2 experts have warned. Many patients will continue to take cannabis illegally to manage symptoms, risking criminalisation, they said.
The move to change medicinal products derived from cannabis to schedule 2 of the 2001 Misuse of Drugs Regulations came after advice from England’s chief medical officer, Sally Davies, and the Advisory Council on the Misuse of Drugs, after several recent cases of children …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.